Cognition

POTUS Cognitive Test Creators Introduce MoCA-XpressO for Public Use

Retrieved on: 
Wednesday, February 21, 2024
Alzheimer's disease, FDA, Ageing, Cognition, Disease, Deficit spending, Motivation, Diagnosis, MCI

For the public concerned with their cognitive performance, or that of a loved one, MoCA Cognition offers the scientifically validated "XpressO by MoCA" app—a rapid cognitive self-assessment tool that can predict performance on the MoCA Test and suggest when to consult with a healthcare professional.

Key Points: 
  • For the public concerned with their cognitive performance, or that of a loved one, MoCA Cognition offers the scientifically validated "XpressO by MoCA" app—a rapid cognitive self-assessment tool that can predict performance on the MoCA Test and suggest when to consult with a healthcare professional.
  • The XpressO by MoCA app was developed in response to growing needs of primary care to detect cognitive impairment, quickly and accurately.
  • This is particularly important considering our aging population, limited public care resources, and new Alzheimer's Disease treatments coming available.
  • Validation studies have demonstrated an approximately 85% accuracy in predicting a MoCA score in the mild cognitive impairment (MCI) range.

Candidates’ aging brains are factors in the presidential race − 4 essential reads

Retrieved on: 
Friday, February 16, 2024
Ageing, University, Dementia, Diet, Molecular biology, Friends, Thought, Loss, Conditional sentence, Exercise, Cell, Brandeis, Memory, Swimming, Cognition, Family, Notifiable disease, University of Florida, Biology

The leading contenders in the 2024 presidential election are two of the three oldest people ever to serve as president.

Key Points: 
  • The leading contenders in the 2024 presidential election are two of the three oldest people ever to serve as president.
  • Both Biden and Trump have faced criticism about what can appear to be obvious signs of aging, including questions about their memory and cognitive abilities.
  • Scholars writing for The Conversation U.S. have discussed various aspects of how aging affects people’s brains.
  • Key factors include the strength of a person’s social connections, as well as their sleeping habits, water consumption, exercise and diet.

Industry-Leading Functional Mushroom Brand, FreshCap, Launches Exclusive Brick-and-Mortar Retail Partnership with GNC

Retrieved on: 
Thursday, February 15, 2024
Acquisition, Name, Social media, Mycelium, DMM, Lion, Beta-glucan, Health, Lion's mane, Human, History, Cognition, GNC, Longevity, Immunity, Triterpene, Partnership

CHICAGO, Feb. 15, 2024 /PRNewswire/ -- FreshCap, the functional mushroom brand utilizing whole fruiting bodies to support a wide range of powerful benefits, announced today a nationwide partnership with GNC. The leading nutritional supplement retailer will have brick-and-mortar exclusivity to FreshCap's best-selling line of high-quality functional mushroom products, all of which are non-GMO, certified organic and analytically tested to guarantee high levels of active beneficial compounds. The products will be available online immediately and rolled out to 1500 retail locations in March.

Key Points: 
  • The products will be available online immediately and rolled out to 1500 retail locations in March.
  • GNC will carry four of FreshCap's beloved mushroom-based products, each formulated to promote health and longevity by increasing immunity, stress relief, cognitive function and more.
  • The GNC-exclusive products include:
    Lion's Mane Capsules ($27.99, 60-count) – the "brain mushroom" used for cognition, focus, and mental clarity.
  • Now the leading voice in mushroom education, FreshCap has a cult following on YouTube with 466K followers and regular programming including "The Mushroom Show."

New Osteopathic Medical School Leverages Learning Science and Technology in Innovative Curriculum

Retrieved on: 
Thursday, February 15, 2024
Physician, Partnership, OCOM, Curriculum, Learning, FACP, Faculty, Patient, Cognition, Teaching, Knowledge, Interview, Kate Campbell, Student, Nursing

CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Orlando College of Osteopathic Medicine (OCOM) will intake its first cohort of 90 students this August and introduce an innovative approach to osteopathic medical education as part of its aim to be the most modern medical school in the country.

Key Points: 
  • TrueLearn's proven solution for maximizing learning and COMLEX-USA® performance is aligned with OCOM's cutting-edge approach, emphasizing evidence-based learning science to deliver optimal outcomes."
  • The school also has a spiral curriculum whereby three to six months after students are first taught information, they will be reassessed through a learning consolidation course.
  • TrueLearn's partnership with OCOM is thus a natural fit as both place high value on learning science principles and maximizing adult learning practices.
  • TrueLearn's proven solution for maximizing learning and COMLEX-USA® performance is aligned with OCOM's cutting-edge approach, emphasizing evidence-based learning science strategies to deliver optimal outcomes."

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, PD, Research, Sale, Tremor, Health care, NMDA, Innovation, Webcast, Plasma, Incidence, GABAA, CIV, Standard of care, Deficit spending, Therapy, European Medicines Agency, Food and Drug Administration, MCI, NEST, HCP, Woman, Schedule, USAN, Postpartum depression, ODD, Safety, Prescription, Insurance, EMA, FDA, Food, Passport, DEA, PAM, DSM-IV codes, Risk, PPD, Patient, MHRA, Cognition, Essential tremor, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 14, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

A Clinically Proven Alzheimer's Treatment Revealed in a Groundbreaking Documentary Narrated by Michael Bublé

Retrieved on: 
Tuesday, February 13, 2024
Amazon Prime Video, Dementia, Memory, Recode, Grammy Awards, Apple TV, Narration, Vimeo, Big Pharma, NHK, Medicine, Patient, Cognition, Clinical trial, Life, Research

BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?

Key Points: 
  • BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?
  • Dr. Bredesen currently has a larger, randomized controlled clinical trial underway that is recruiting patients from six locations across the US.
  • Patients following the Bredesen Protocol and Dr Bredesen's ReCODE Program were profiled in the new documentary film, Memories for Life - Reversing Alzheimer's, which is narrated by Grammy-winner Michael Bublé.
  • The film was initially produced for NHK in Japan, where it originally aired, with additional filming, editing, and narration from Michael Bublé included for the North American market.

Presidents' Cognition and Appropriate Use of the MoCA Test Content

Retrieved on: 
Tuesday, February 13, 2024
Administration, Cognition, Certification, Patient

The MoCA Test is a copyrighted work owned by MoCA Cognition.

Key Points: 
  • The MoCA Test is a copyrighted work owned by MoCA Cognition.
  • The MoCA Test cannot be reproduced, or distributed, in whole or in part, by others, including the media, without express permission from MoCA Cognition.
  • The MoCA Test was designed and explicitly meant only for use by healthcare professionals to assess their patients.
  • Administration, scoring and interpretation of the MoCA Test are reserved to healthcare professionals and require specific training and certification.

uMotif and MoCA Cognition Bring Modern, Patient-Centric eCOA/ePRO, MoCA Test and New XpressO Mobile App to Clinical Trials, Real-World Studies for CNS-Related Conditions

Retrieved on: 
Monday, February 12, 2024
Consensus, Cognition, Schizophrenia, MIS, Deficit spending, ChromeOS, Neurology, CNS, Patient, DSM-IV codes, Research, Consensus decision-making, Partnership

BOSTON and LONDON, Feb. 12, 2024 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest-growing companies – and MoCA Cognition, creators of the leading test for early cognitive impairment detection – are collaborating to make it easier for sponsors and CROs to capture quality cognitive function and eCOA/ePRO data for CNS research.

Key Points: 
  • The company continues to deepen its portfolio across CNS through its partnership with MoCA Cognition, whose MoCA Test (Montreal Cognitive Assessment) was ranked No.
  • MoCA Cognition CEO and Neurologist Dr. Ziad Nasreddine created the MoCA Test in 1996 to help clinicians and researchers rapidly scan multiple cognitive domains and detect impairment.
  • The standard MoCA test is administered to patients, and can be uploaded into the uMotif platform for central rating and review.
  • Solutions using the standard MoCA test and the uMotif platform are available for immediate deployment.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Sunday, February 11, 2024
Pomerantz, City University, Court, Person, FDA, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.